Advanced Pharmacology Fundamentals
Week 1 Practice Questions (6–200) with Rationales
Original study questions covering pharmacokinetics, pharmacodynamics, drug interactions,
adverse reactions, special populations, and dosing principles.
Pharmacokinetics: Absorption & Distribution
1. A patient is prescribed a drug that is highly protein-bound (95%). The patient also has
hypoalbuminemia. What is the most likely clinical consequence?
A. Decreased drug effect due to reduced absorption
B. Increased free drug concentration and risk of toxicity
C. Prolonged half-life due to increased protein binding
D. No clinical effect since protein binding doesn't affect free drug
Answer: B
Rationale: Only unbound ("free") drug is pharmacologically active. When albumin is low, there
is less protein available to bind the drug, so a larger fraction remains free in circulation. This
increases the amount of active drug reaching receptors, raising the risk of toxicity — even
though the total (bound + unbound) drug concentration may look normal on a lab report.
2. Which pharmacokinetic phase refers to the movement of a drug from its site of
administration into the bloodstream?
A. Distribution
B. Absorption
,C. Metabolism
D. Excretion
Answer: B
Rationale: Absorption is defined as the process by which a drug moves from its administration
site (GI tract, muscle, subcutaneous tissue, etc.) into systemic circulation. Distribution refers to
movement from the blood into tissues, metabolism to biotransformation (often hepatic), and
excretion to elimination from the body (often renal).
3. A drug has a half-life of 6 hours. Approximately how long will it take to reach steady-
state concentration with regular dosing?
A. 6 hours
B. 12 hours
C. 24–30 hours (4–5 half-lives)
D. 48 hours minimum regardless of half-life
Answer: C
Rationale: Steady state is reached after approximately 4–5 half-lives of consistent dosing,
regardless of dose size — only the half-life value changes the time required. With a 6-hour half-
life, 4–5 half-lives = 24–30 hours.
4. First-pass metabolism primarily affects which route of administration?
A. Intravenous
B. Oral
C. Sublingual
D. Transdermal
Answer: B
Rationale: Orally administered drugs are absorbed through the GI tract and transported via the
,portal vein directly to the liver before reaching systemic circulation, where a significant portion
may be metabolized before ever reaching target tissues. IV drugs bypass this entirely; sublingual
and transdermal routes also largely avoid first-pass metabolism because they don't route through
the portal circulation first.
5. A nurse is reviewing a new order for a medication with a narrow therapeutic index.
What is the priority nursing consideration?
A. The drug can be given without monitoring since dosing is standardized
B. Small changes in dose or blood level can cause toxicity or therapeutic failure
C. The drug has a wide margin of safety
D. Therapeutic drug monitoring is unnecessary
Answer: B
Rationale: A narrow therapeutic index means the difference between an effective dose and a
toxic dose is small. Drugs like warfarin, digoxin, and lithium require close monitoring of blood
levels and clinical response because minor variations (from interactions, renal/hepatic function
changes, or adherence) can quickly shift the patient from sub-therapeutic to toxic.
6. A patient with severe peripheral edema is started on a hydrophilic
medication. What effect will the edema most likely have on drug distribution?
A. Decreased volume of distribution and higher serum levels
B. Increased volume of distribution and potentially lower serum levels than expected
C. No effect, since edema only affects lipophilic drugs
D. Faster onset of action due to increased blood flow
Answer: B
, Rationale: Hydrophilic drugs distribute into extracellular fluid. Edema expands the
extracellular fluid compartment, increasing the apparent volume of distribution. This can dilute
serum concentrations, potentially producing sub-therapeutic levels if dosing isn't adjusted.
7. Which factor most directly affects the rate of drug absorption after
intramuscular injection?
A. Hepatic blood flow
B. Site vascularity (blood flow to the muscle)
C. Renal clearance
D. Plasma protein concentration
Answer: B
Rationale: IM absorption depends on diffusion from the injection site into surrounding
capillaries. Muscles with greater blood flow (e.g., deltoid) absorb drugs faster than those with
less (e.g., gluteal), independent of hepatic or renal function.
8. A lipophilic drug is administered to a patient with a high percentage of
body fat. What is the expected pharmacokinetic effect?
A. Shorter half-life due to rapid excretion
B. Larger volume of distribution and potentially prolonged half-life
C. Decreased volume of distribution
D. No change in distribution
Answer: B
Rationale: Lipophilic drugs partition into adipose tissue. More body fat provides a larger
reservoir for the drug to distribute into, increasing volume of distribution. Because half-life is
proportional to volume of distribution divided by clearance, this often prolongs the drug's half-
life.
9. Enteric-coated tablets are designed to accomplish which of the following?
A. Increase the rate of gastric absorption
Week 1 Practice Questions (6–200) with Rationales
Original study questions covering pharmacokinetics, pharmacodynamics, drug interactions,
adverse reactions, special populations, and dosing principles.
Pharmacokinetics: Absorption & Distribution
1. A patient is prescribed a drug that is highly protein-bound (95%). The patient also has
hypoalbuminemia. What is the most likely clinical consequence?
A. Decreased drug effect due to reduced absorption
B. Increased free drug concentration and risk of toxicity
C. Prolonged half-life due to increased protein binding
D. No clinical effect since protein binding doesn't affect free drug
Answer: B
Rationale: Only unbound ("free") drug is pharmacologically active. When albumin is low, there
is less protein available to bind the drug, so a larger fraction remains free in circulation. This
increases the amount of active drug reaching receptors, raising the risk of toxicity — even
though the total (bound + unbound) drug concentration may look normal on a lab report.
2. Which pharmacokinetic phase refers to the movement of a drug from its site of
administration into the bloodstream?
A. Distribution
B. Absorption
,C. Metabolism
D. Excretion
Answer: B
Rationale: Absorption is defined as the process by which a drug moves from its administration
site (GI tract, muscle, subcutaneous tissue, etc.) into systemic circulation. Distribution refers to
movement from the blood into tissues, metabolism to biotransformation (often hepatic), and
excretion to elimination from the body (often renal).
3. A drug has a half-life of 6 hours. Approximately how long will it take to reach steady-
state concentration with regular dosing?
A. 6 hours
B. 12 hours
C. 24–30 hours (4–5 half-lives)
D. 48 hours minimum regardless of half-life
Answer: C
Rationale: Steady state is reached after approximately 4–5 half-lives of consistent dosing,
regardless of dose size — only the half-life value changes the time required. With a 6-hour half-
life, 4–5 half-lives = 24–30 hours.
4. First-pass metabolism primarily affects which route of administration?
A. Intravenous
B. Oral
C. Sublingual
D. Transdermal
Answer: B
Rationale: Orally administered drugs are absorbed through the GI tract and transported via the
,portal vein directly to the liver before reaching systemic circulation, where a significant portion
may be metabolized before ever reaching target tissues. IV drugs bypass this entirely; sublingual
and transdermal routes also largely avoid first-pass metabolism because they don't route through
the portal circulation first.
5. A nurse is reviewing a new order for a medication with a narrow therapeutic index.
What is the priority nursing consideration?
A. The drug can be given without monitoring since dosing is standardized
B. Small changes in dose or blood level can cause toxicity or therapeutic failure
C. The drug has a wide margin of safety
D. Therapeutic drug monitoring is unnecessary
Answer: B
Rationale: A narrow therapeutic index means the difference between an effective dose and a
toxic dose is small. Drugs like warfarin, digoxin, and lithium require close monitoring of blood
levels and clinical response because minor variations (from interactions, renal/hepatic function
changes, or adherence) can quickly shift the patient from sub-therapeutic to toxic.
6. A patient with severe peripheral edema is started on a hydrophilic
medication. What effect will the edema most likely have on drug distribution?
A. Decreased volume of distribution and higher serum levels
B. Increased volume of distribution and potentially lower serum levels than expected
C. No effect, since edema only affects lipophilic drugs
D. Faster onset of action due to increased blood flow
Answer: B
, Rationale: Hydrophilic drugs distribute into extracellular fluid. Edema expands the
extracellular fluid compartment, increasing the apparent volume of distribution. This can dilute
serum concentrations, potentially producing sub-therapeutic levels if dosing isn't adjusted.
7. Which factor most directly affects the rate of drug absorption after
intramuscular injection?
A. Hepatic blood flow
B. Site vascularity (blood flow to the muscle)
C. Renal clearance
D. Plasma protein concentration
Answer: B
Rationale: IM absorption depends on diffusion from the injection site into surrounding
capillaries. Muscles with greater blood flow (e.g., deltoid) absorb drugs faster than those with
less (e.g., gluteal), independent of hepatic or renal function.
8. A lipophilic drug is administered to a patient with a high percentage of
body fat. What is the expected pharmacokinetic effect?
A. Shorter half-life due to rapid excretion
B. Larger volume of distribution and potentially prolonged half-life
C. Decreased volume of distribution
D. No change in distribution
Answer: B
Rationale: Lipophilic drugs partition into adipose tissue. More body fat provides a larger
reservoir for the drug to distribute into, increasing volume of distribution. Because half-life is
proportional to volume of distribution divided by clearance, this often prolongs the drug's half-
life.
9. Enteric-coated tablets are designed to accomplish which of the following?
A. Increase the rate of gastric absorption
